OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Sodium chloride 0.9%, solution for infusion, 5% Dextrose, solution for infusion
CA209-8Y8
Phase 3 small_molecule active
Quick answer
OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Sodium chloride 0.9%, solution for infusion, 5% Dextrose, solution for infusion for Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active